{"organizations": [], "uuid": "869bda4f837e82b886b4de1f9b42513f7446c2f5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-immunogen-inc-reports-qtrly-net-lo/brief-immunogen-inc-reports-qtrly-net-loss-per-common-share-basic-and-diluted-of-0-11-idUSASB0C50G", "country": "US", "domain_rank": 408, "title": "BRIEF-Immunogen Inc Reports Qtrly Net Loss Per Common Share, Basic And Diluted Of $0.11‍​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-09T13:40:00.000+02:00", "replies_count": 0, "uuid": "869bda4f837e82b886b4de1f9b42513f7446c2f5"}, "author": "", "url": "https://www.reuters.com/article/brief-immunogen-inc-reports-qtrly-net-lo/brief-immunogen-inc-reports-qtrly-net-loss-per-common-share-basic-and-diluted-of-0-11-idUSASB0C50G", "ord_in_thread": 0, "title": "BRIEF-Immunogen Inc Reports Qtrly Net Loss Per Common Share, Basic And Diluted Of $0.11‍​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-immunogen inc", "sentiment": "negative"}, {"name": "immunogen inc", "sentiment": "none"}, {"name": "immunogen", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 41 AM / in 5 minutes BRIEF-Immunogen Inc Reports Qtrly Net Loss Per Common Share, Basic And Diluted Of $0.11‍​   Immunogen Inc: \n* IMMUNOGEN REPORTS PIPELINE PROGRESS AND 2017 OPERATING RESULTS \n* QTRLY NET LOSS PER COMMON SHARE, BASIC AND DILUTED $0.11‍​ * SEES FY 2018 REVENUE $60 MILLION TO $65 MILLION \n* QTRLY TOTAL REVENUES $39.45 MILLION VERSUS $13.85 MILLION \n* IMMUNOGEN - EXPECTS CURRENT CASH COMBINED WITH EXPECTED CASH REVS FROM PARTNERS & COLLABORATORS WILL ENABLE CO TO FUND ITS OPERATIONS INTO Q4 OF 2019 \n* Q4 EARNINGS PER SHARE VIEW $-0.12, REVENUE VIEW $32.7 MILLION -- THOMSON REUTERS I/B/E/S \n* SEES CASH AND CASH EQUIVALENTS AT DECEMBER 31, 2018 BETWEEN $115 MILLION AND $120 MILLION \n* FY2018 REVENUE VIEW $58.7 MILLION -- THOMSON REUTERS I/B/E/S \n* IMMUNOGEN SAYS TO MOVE TO OPERATING MODEL THAT WILL RELY ON EXTERNAL MANUFACTURING AND QUALITY TESTING FOR DRUG SUBSTANCE \n* IMMUNOGEN - TO MOVE TO OPERATING MODEL THAT WILL ALSO RELY ON EXTERNAL MANUFACTURING AND QUALITY TESTING FOR DRUG PRODUCT FOR DEVELOPMENT PROGRAMS \n* DECOMMISSIONING NORWOOD FACILITY WILL RESULT IN ANTICIPATED COST SAVINGS OF OVER $20 MILLION DURING NEXT FIVE YEARS \n* IMMUNOGEN -IMPLEMENTING ‍NEW OPERATING MODEL TO LEAD TO RAMP-DOWN OF MANUFACTURING, QUALITY ACTIVITIES AT NORWOOD, MASSACHUSETTS FACILITY BY 2018 END​ \n* ‍ IMPLEMENTATION OF NEW OPERATING MODEL WILL LEAD TO FULL EXIT AT NORWOOD, MASSACHUSETTS FACILITY BY EARLY 2019​ \n* Q4 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S  ", "external_links": [], "published": "2018-02-09T13:40:00.000+02:00", "crawled": "2018-02-09T13:51:52.002+02:00", "highlightTitle": ""}